Is immune therapy changing the way we think about early bladder cancer?
Early bladder cancer, including muscle invasive and non-muscle invasive disease is prevalent and a huge cancer healthcare issue.
| Organiser | European School of Urology |
|---|---|
| CME | No accreditation |
| Duration | Approx. 40 minutes |
Multimodality treatments have been employed, including chemotherapy, BCG, surgery and radiotherapy.
Aggressive early disease remains lethal. The immune checkpoint inhibitors have changed treatment of metastatic disease. The biology and initial data suggests they could be even more active in early disease. The data supporting this is discussed in this recorded webinar.
Presenter: Dr. Thomas Powles